Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression

Journal of Immunology

Volumn 183, Issue 6, 2009, Pages 3672-3681

  Nashold, Faye E ^a   Spach, Karen M ^b   Spanier, Justin A ^a   Hayes, Colleen E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COLECALCIFEROL; ESTRADIOL; PLACEBO; CALCITRIOL RECEPTOR; ESTROGEN; VITAMIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; ESTROGEN SYNTHESIS; FEMALE; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; ANIMAL; BIOSYNTHESIS; CENTRAL NERVOUS SYSTEM; HUMAN; MALE; METABOLISM; PHYSIOLOGY; SEX DIFFERENCE;

ANIMALS; CENTRAL NERVOUS SYSTEM; CHOLECALCIFEROL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; MALE; MICE; OVARIECTOMY; RECEPTORS, CALCITRIOL; SEX FACTORS; VITAMINS;

EID: 70349336167     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901351     Document Type: Article

References (83)

1. Hauser, S. L., and J. R. Oksenberg. 2006. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52: 61-76. (Pubitemid 44466355)
2. McElroy, J. P., and J. R. Oksenberg. 2008. Multiple sclerosis genetics. Curr. Top. Microbiol. Immunol. 318: 45-72.
3. Ebers, G. C., D. E. Bulman, A. D. Sadovnick, D. W. Paty, S. Warren, W. Hader, T. J. Murray, T. P. Seland, P. Duquette, T. Grey, et al. 1986. A population-based study of multiple sclerosis in twins. N. Engl. J. Med. 315: 1638-1642. (Pubitemid 17052896)
4. Acheson, E. D., C. A. Bachrach, and F. M. Wright. 1960. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiatry Scand. 35(Suppl. 147): 132-147.
5. Hammond, S. R., D. R. English, and J. G. McLeod. 2000. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 123: 968-974.
6. Ebers, G. C. 2008. Environmental factors and multiple sclerosis. Lancet Neurol. 7: 268-277.
7. Freedman, D. M., M. Dosemeci, and M. C. Alavanja. 2000. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup. Environ. Med. 57: 418-421.
8. van der Mei, I. A., A. L. Ponsonby, T. Dwyer, L. Blizzard, R. Simmons, B. V. Taylor, H. Butzkueven, and T. Kilpatrick. 2003. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Br. Med. J. 327: 316.
9. Hayes, C. E., M. T. Cantorna, and H. F. DeLuca. 1997. Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 216: 21-27.
10. Prosser, D. E., and G. Jones. 2004. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 29: 664-673.
11. 3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 57: 1308-1310.
12. 3 receptors in human leukocytes. Science 221: 1181-1183.
13. Hayes, C. E. 2000. Vitamin D: a natural inhibitor of multiple sclerosis. Proc. Nutr. Soc. 59: 531-535.
14. Hayes, C. E., F. E. Nashold, K. M. Spach, and L. B. Pedersen. 2003. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-Grand) 49: 277-300.
15. Munger, K. L., L. I. Levin, B. W. Hollis, N. S. Howard, and A. Ascherio. 2006. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. J. Am. Med. Assoc. 296: 2832-2838.
16. Embry, A. F., L. R. Snowdon, and R. Vieth. 2000. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 48: 271-272.
17. VanAmerongen, B. M., C. D. Dijkstra, P. Lips, and C. H. Polman. 2004. Multiple sclerosis and vitamin D: an update. Eur. J. Clin. Nutr. 58: 1095-1109.
18. Soilu-Hanninen, M., L. Airas, I. Mononen, A. Heikkila, M. Viljanen, and A. Hanninen. 2005. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11: 266-271.
19. Soilu-Hanninen, M., M. Laaksonen, I. Laitinen, J. P. Eralinna, E. M. Lilius, and I. Mononen. 2008. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 79: 152-157.
20. Tremlett, H., I. A. van der Mei, F. Pittas, L. Blizzard, G. Paley, D. Mesaros, R. Woodbaker, M. Nunez, T. Dwyer, B. V. Taylor, and A. L. Ponsonby. 2008. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 31: 271-279.
21. Smolders, J., P. Menheere, A. Kessels, J. Damoiseaux, and R. Hupperts. 2008. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 14: 1220-1224.
22. 3 with calcium supplementation in patients with multiple sclerosis. Mult. Scler. 14: S34.
23. Torkildsen, O., P. M. Knappskog, H. I. Nyland, and K. M. Myhr. 2008. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch. Neurol. 65: 809-811.
24. 3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76: 1294-1296.
25. Whitacre, C. C. 2001. Sex differences in autoimmune disease. Nat. Immunol. 2: 777-780.
26. Wallin, M. T., W. F. Page, and J. F. Kurtzke. 2004. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 55: 65-71.
27. Grytten, N., S. B. Glad, J. H. Aarseth, H. Nyland, R. Midgard, and K. M. Myhr. 2006. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology 66: 182-186.
28. Orton, S. M., B. M. Herrera, I. M. Yee, W. Valdar, S. V. Ramagopalan, A. D. Sadovnick, and G. C. Ebers. 2006. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5: 932-936.
29. Alonso, A., and M. A. Hernan. 2008. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71: 129-135.
30. Roger, E., and P. Duquette. 2008. Multiple sclerosis: increase over time in the ratio of women to men in patients with an early onset. Mult. Scler. 14: S63.
31. Thomas, T., and B. Banwell. 2008. Multiple sclerosis in children. Semin. Neurol. 28: 69-83.
32. Voskuhl, R. R., and K. Palaszynski. 2001. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist 7: 258-270.
33. Soldan, S. S., A. I. Alvarez Retuerto, N. L. Sicotte, and R. R. Voskuhl. 2003. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol. 171: 6267-6274.
34. Offner, H., and M. Polanczyk. 2006. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann. NY Acad. Sci. 1089: 343-372.
35. Sicotte, N. L., B. S. Giesser, V. Tandon, R. Klutch, B. Steiner, A. E. Drain, D. W. Shattuck, L. Hull, H. J. Wang, R. M. Elashoff, et al. 2007. Testosterone treatment in multiple sclerosis: a pilot study. Arch. Neurol. 64: 683-688.
36. Gold, S. M., S. Chalifoux, B. S. Giesser, and R. R. Voskuhl. 2008. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J. Neuroinflammation 5: 32.
37. 3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 175: 4119-4126.
38. Kragt, J., B. van Amerongen, J. Killestein, C. Dijkstra, B. Uitdehaag, C. Polman, and P. Lips. 2009. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult. Scler. 15: 9-15.
39. McFarlin, D. E., S. E. Blank, and R. F. Kibler. 1974. Recurrent experimental allergic encephalomyelitis in the Lewis rat. J. Immunol. 113: 712-715.
40. Polanczyk, M. J., C. Hopke, J. Huan, A. A. Vandenbark, and H. Offner. 2005. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J. Neuroimmunol. 170: 85-92.
41. 3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 103: 171-179.
42. Overbergh, L., B. Decallonne, D. Valckx, A. Verstuyf, J. Depovere, J. Laureys, O. Rutgeerts, R. Saint-Arnaud, R. Bouillon, and C. Mathieu. 2000. Identification and immune regulation of 25-hydroxyvitamin D-1-α- hydroxylase in murine macrophages. Clin. Exp. Immunol. 120: 139-146.
43. Overbergh, L., D. Valckx, M. Waer, and C. Mathieu. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11: 305-312.
44. Offner, H., K. Adlard, A. Zamora, and A. A. Vandenbark. 2000. Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. J. Clin. Invest. 105: 1465-1472.
45. Ghayee, H. K., and R. J. Auchus. 2007. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev. Endocr. Metab. Disord. 8: 289-300.
46. Zamvil, S., P. Nelson, J. Trotter, D. Mitchell, R. Knobler, R. Fritz, and L. Steinman. 1985. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317: 355-358.
47. Mendel, I., N. Kerlero de Rosbo, and A. Ben-Nun. 1995. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells. Eur. J. Immunol. 25: 1951-1959.
48. Bebo, B. F., Jr., A. Fyfe-Johnson, K. Adlard, A. G. Beam, A. A. Vandenbark, and H. Offner. 2001. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol. 166: 2080-2089.
49. Omdahl, J. L., H. A. Morris, and B. K. May. 2002. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu. Rev. Nutr. 22: 139-166.
50. Zhao, S., and R. D. Fernald. 2005. Comprehensive algorithm for quantitative real-time polymerase chain reaction. J. Comput. Biol. 12: 1047-1064.
51. Kinuta, K., H. Tanaka, T. Moriwake, K. Aya, S. Kato, and Y. Seino. 2000. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 141: 1317-1324. (Pubitemid 32269098)
52. Yague, J. G., L. M. Garcia-Segura, and I. Azcoitia. 2009. Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells. Endocrine 35: 252-261.
53. Barrera, D., E. Avila, G. Hernandez, A. Halhali, B. Biruete, F. Larrea, and L. Diaz. 2007. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J. Steroid Biochem. Mol. Biol. 103: 529-532. (Pubitemid 46401361)
54. Liel, Y., S. Kraus, J. Levy, and S. Shany. 1992. Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8). Endocrinology 130: 2597-2601.
55. 3 receptors in bone cells: changes with aging and hormone deprivation. Biochem. Biophys. Res. Commun. 299: 446-454.
56. Liel, Y., S. Shany, P. Smirnoff, and B. Schwartz. 1999. Estrogen increases 1,25- dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 140: 280-285. (Pubitemid 29011170)
57. Smirnoff, P., Y. Liel, J. Gnainsky, S. Shany, and B. Schwartz. 1999. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol. Res. 11: 255-264.
58. Schwartz, B., P. Smirnoff, S. Shany, and Y. Liel. 2000. Estrogen controls expression and bioresponse of 1,25-dihydroxyvitamin D receptors in the rat colon. Mol. Cell. Biochem. 203: 87-93. (Pubitemid 30111780)
59. Zhou, Y., R. Q. Ye, D. H. Cai, and H. Zhang. 2002. Effect of estrogen and progesterone on the expression of 1,25-dihydroxyvitamin D receptors mRNA in the liver of ovariectomized rats. Di Yi Jun Yi Da Xue Xue Bao 22: 521-523.
60. 3 receptors in T 47D breast cancer cells. J. Steroid Biochem. Mol. Biol. 45: 257-263.
61. Byrne, I. M., L. Flanagan, M. P. Tenniswood, and J. Welsh. 2000. Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology 141: 2829-2836. (Pubitemid 32250445)
62. Elenkov, I. J., R. L. Wilder, V. K. Bakalov, A. A. Link, M. A. Dimitrov, S. Fisher, M. Crane, K. S. Kanik, and G. P. Chrousos. 2001. IL-12, TNF-α, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab. 86: 4933-4938.
63. Offner, H. 2004. Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis. J. Neurosci. Res. 78: 603-624. (Pubitemid 39657579)
64. 3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J. Neurosci. Res. 85: 2480-2490.
65. Matejuk, A., K. Adlard, A. Zamora, M. Silverman, A. A. Vandenbark, and H. Offner. 2001. 17β-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. J. Neurosci. Res. 65: 529-542. (Pubitemid 32847146)
66. 3 prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119: 16-29.
67. + regulatory T cell compartment. J. Immunol. 173: 2227-2230.
68. Matejuk, A., A. C. Bakke, C. Hopke, J. Dwyer, A. A. Vandenbark, and H. Offner. 2004. Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J. Neurosci. Res. 77: 119-126. (Pubitemid 38850062)
69. 3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol. 177: 6030-6037.
70. Garcion, E., N. Wion-Barbot, C. N. Montero-Menei, F. Berger, and D. Wion. 2002. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 13: 100-105.
71. 3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol. Genomics 18: 141-151.
72. Ito, A., B. F. Bebo, Jr., A. Matejuk, A. Zamora, M. Silverman, A. Fyfe-Johnson, and H. Offner. 2001. Estrogen treatment down-regulates TNF-α production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J. Immunol. 167: 542-552.
73. Liu, H. B., K. K. Loo, K. Palaszynski, J. Ashouri, D. B. Lubahn, and R. R. Voskuhl. 2003. Estrogen receptor α mediates estrogen's immune protection in autoimmune disease. J. Immunol. 171: 6936-6940.
74. Polanczyk, M., A. Zamora, S. Subramanian, A. Matejuk, D. L. Hess, E. P. Blankenhorn, C. Teuscher, A. A. Vandenbark, and H. Offner. 2003. The protective effect of 17β-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-α. Am. J. Pathol. 163: 1599-1605.
75. Polanczyk, M. J., R. E. Jones, S. Subramanian, M. Afentoulis, C. Rich, M. Zakroczymski, P. Cooke, A. A. Vandenbark, and H. Offner. 2004. T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis. Am. J. Pathol. 165: 2069-2077.
76. Acheson, E. D. 1977. Epidemiology of multiple sclerosis. Br. Med. Bull. 33: 9-14.
77. Noonan, C. W., S. J. Kathman, and M. C. White. 2002. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 58: 136-138.
78. Simmons, R. D., C. A. Hall, P. Gleeson, G. Everard, R. F. Casse, and E. D. O'Brien. 2001. Prevalence survey of multiple sclerosis in the Australian Capital Territory. Intern. Med. J. 31:161-167.
79. Hirst, C., G. Ingram, T. Pickersgill, R. Swingler, D. A. Compston, and N. P. Robertson. 2009. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J. Neurol. Neurosurg. Psychiatry 80: 386-391.
80. Midgard, R., T. Riise, C. Svanes, G. Kvale, and H. Nyland. 1996. Incidence of multiple sclerosis in More and Romsdal, Norway from 1950 to 1991: an age-period-cohort analysis. Brain 119: 203-211.
81. Pugliatti, M., S. Sotgiu, G. Solinas, P. Castiglia, M. I. Pirastru, B. Murgia, L. Mannu, G. Sanna, and G. Rosati. 2001. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol. Scand. 103: 20-26.
82. Herrera, B. M., M. Z. Cader, D. A. Dyment, J. T. Bell, G. C. Deluca, C. J. Willer, M. R. Lincoln, S. V. Ramagopalan, M. Chao, S. M. Orton, A. D. Sadovnick, and G. C. Ebers. 2007. Multiple sclerosis susceptibility and the X chromosome. Mult. Scler. 13: 856-864.
83. Holick, M. F. 2003. Vitamin D: A millenium perspective. J. Cell. Biochem. 88: 296-307.